ASSESSMENT OF PHARMACEUTICAL QUALITY AND RELEASE KINETICS OF METOPROLOL TARTRATE EXTENDED RELEASE TABLETS AVAILABLE IN TURKISH DRUG MARKET
Abstract
Cardioselective β-adrenergic blocker metoprolol tartrate, is used in the treatment of different diseases such as cardiac arrhythmias, hypertension, heart failure, angina pectoris, migraine, and hyperthyroidism. Beside dosage forms of the parenteral ampoule and conventional tablets of different manufacturers, there are extended release tablets of metoprolol tartrate in the Turkish Drug Market. In this research work, comparative quality control studies of metoprolol tartrate extended release tablets (original and generic) produced by two different pharmaceutical companies in the Turkey were carried out and evaluated according to the related guidelines. Thickness and diameter, hardness, weight variation, friability, content uniformity and dissolution rate were examined as quality control parameters. A new validated HPLC method for the quantification of metoprolol tartrate has been developed. An ACE column (C18, 5 µm, 250x4.6 mm) and acetonitrile:phosphate buffer (30:70, v/v) mobile phase were used for the determination of metoprolol tartrate. The tablets showed extended release for 8 hours (70.74% release from drug A, 76.87% from the drug B). Both products have acceptable hardness, friability and weight variation values. Content of the active ingredient of the tablets was consistent with label claim (99.45% for drug A and 96.45% for drug B). The dissolution data were evaluated by model dependent and model independent methods using DDSolver program. The obtained results showed that release kinetics of both drugs were well fitted with the Korsmeyer-Peppas model.
Keywords
Metoprolol tartrate, Modified release, Pharmaceutical quality control, Release kinetics, DDSolver
Thanks
Ayse Gencer was supported by TUBITAK 2211-A grant. This study is the part of Ayşe Gencer’s graduation project.
References
- [1]Haleem RM, Salem MY, Fatahallah FA, Abdelfattah LE. Quality in the pharmaceutical industry-A literature review. Saudi Pharmaceutical Journal 2015;23(5):463-469.
- [2]Bonsmann C, Haefele-Abah C, Liedtke C. Supplier Auditing: A shared experience of quality assurance. Pharmalink 2010;10(1):8-10.
- [3]Uddin MS. Quality control of pharmaceuticals: compendial standards and specifications: Scholars' Press; 2017.
- [4]Food and Drug Administration, HHS. Current good manufacturing practices, quality control procedures, quality factors, notification requirements, and records and reports, for infant formula. Final rule. Federal register, 2014; 79(111), 33057.
- [5]World Health Organization. Quality assurance of pharmaceuticals: A compendium of guidelines and related materials. WHO, 2004.
- [6]ICH Guideline. Q10: Pharmaceutical quality system: Current Step 2008;4.
- [7]Akgeyik E, Kaynak MS, Çelebier M, Altınöz S, Şahin S. Evaluation of pharmaceutical quality of conventional dosage forms containing paracetamol and caffeine available in the Turkish drug market. Dissolution Technology 2016;23(2):36-41.
- [8]Awofisayo SO, Awofisayo OA, Eyen N, Udoh IE. Comparative assessment of the quality control measurements of multisource ofloxacin tablets marketed in Nigeria. Dissolution Technology 2010; 17:20-25.
- [9]Dewan S, Alam A, Ahamed S. A comparative quality control study on conventional ibuprofen tablets available in Bangladeshi pharma market. International Research Journal of Pharmacy 2013;4(1):96-98.
- [10]Feroz M, Razvi N, Ghayas S, Anjum F, Ghazal L, Siddiqui SA. Assessment of pharmaceutical quality control and equivalence of various brands of amlodipine besylate (5 mg) tablets available in the Pakistani market under biowaiver conditions. International Journal of Pharmaceutical Sciences 2014;6(2):909-913.